• Medientyp: E-Artikel
  • Titel: Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
  • Beteiligte: Fougeroux, Cyrielle; Goksøyr, Louise; Idorn, Manja; Soroka, Vladislav; Myeni, Sebenzile K.; Dagil, Robert; Janitzek, Christoph M.; Søgaard, Max; Aves, Kara-Lee; Horsted, Emma W.; Erdoğan, Sayit Mahmut; Gustavsson, Tobias; Dorosz, Jerzy; Clemmensen, Stine; Fredsgaard, Laurits; Thrane, Susan; Vidal-Calvo, Elena E.; Khalifé, Paul; Hulen, Thomas M.; Choudhary, Swati; Theisen, Michael; Singh, Susheel K.; Garcia-Senosiain, Asier; Van Oosten, Linda; [...]
  • Erschienen: Springer Science and Business Media LLC, 2021
  • Erschienen in: Nature Communications, 12 (2021) 1
  • Sprache: Englisch
  • DOI: 10.1038/s41467-020-20251-8
  • ISSN: 2041-1723
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractThe rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. RBD antigens are displayed on AP205 CLPs through a split-protein Tag/Catcher, ensuring unidirectional and high-density display of RBD. Both soluble recombinant RBD and RBD displayed on CLPs bind the ACE2 receptor with nanomolar affinity. Mice are vaccinated with soluble RBD or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. The RBD-CLP vaccines induce higher levels of serum anti-spike antibodies than the soluble RBD vaccines. Remarkably, one injection with our lead RBD-CLP vaccine in mice elicits virus neutralization antibody titers comparable to those found in patients that had recovered from COVID-19. Following booster vaccinations, the virus neutralization titers exceed those measured after natural infection, at serum dilutions above 1:10,000. Thus, the RBD-CLP vaccine is a highly promising candidate for preventing COVID-19.
  • Zugangsstatus: Freier Zugang